

## HR 1188

### FLAT Prices Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 13, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Feb 14, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/1188>

### Sponsor

**Name:** Rep. Golden, Jared F. [D-ME-2]

**Party:** Democratic • **State:** ME • **Chamber:** House

### Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Casten, Sean [D-IL-6]	D · IL		Feb 13, 2019
Rep. Cisneros, Gilbert Ray, Jr. [D-CA-39]	D · CA		Feb 13, 2019
Rep. Pingree, Chellie [D-ME-1]	D · ME		Feb 13, 2019
Rep. Rose, Max [D-NY-11]	D · NY		Feb 13, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Feb 13, 2019
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Jun 6, 2019
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Oct 31, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 14, 2019

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
116 S 366	Identical bill	Feb 6, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S921-922)

## Forcing Limits on Abusive and Tumultuous Prices or the FLAT Prices Act

This bill directs the Food and Drug Administration to reduce the market exclusivity of an approved prescription drug if the drug manufacturer increases the drug's price by more than a specified percentage. This reduction may be waived under specified circumstances.

### Actions Timeline

---

- **Feb 14, 2019:** Referred to the Subcommittee on Health.
- **Feb 13, 2019:** Introduced in House
- **Feb 13, 2019:** Referred to the House Committee on Energy and Commerce.